Growth Metrics

Emergent BioSolutions (EBS) Cash from Investing Activities (2016 - 2026)

Emergent BioSolutions has reported Cash from Investing Activities over the past 17 years, most recently at -$2.4 million for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 104.03% year-over-year to -$2.4 million; the TTM value through Mar 2026 reached $7.5 million, down 96.16%, while the annual FY2025 figure was $69.4 million, 44.57% down from the prior year.
  • Cash from Investing Activities for Q1 2026 was -$2.4 million at Emergent BioSolutions, up from -$3.9 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $257.7 million in Q2 2023 and troughed at -$271.6 million in Q3 2022.
  • A 5-year average of $1.4 million and a median of -$4.6 million in 2024 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: crashed 392.03% in 2022 and later skyrocketed 902.8% in 2023.
  • Year by year, Cash from Investing Activities stood at -$45.4 million in 2022, then skyrocketed by 74.89% to -$11.4 million in 2023, then surged by 350.88% to $28.6 million in 2024, then plummeted by 113.64% to -$3.9 million in 2025, then surged by 38.46% to -$2.4 million in 2026.
  • Business Quant data shows Cash from Investing Activities for EBS at -$2.4 million in Q1 2026, -$3.9 million in Q4 2025, and -$3.4 million in Q3 2025.